JP2024527620A5 - - Google Patents

Info

Publication number
JP2024527620A5
JP2024527620A5 JP2024502131A JP2024502131A JP2024527620A5 JP 2024527620 A5 JP2024527620 A5 JP 2024527620A5 JP 2024502131 A JP2024502131 A JP 2024502131A JP 2024502131 A JP2024502131 A JP 2024502131A JP 2024527620 A5 JP2024527620 A5 JP 2024527620A5
Authority
JP
Japan
Prior art keywords
csc
tap
cancer
molecule
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024502131A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024527620A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CA2022/051068 external-priority patent/WO2023023840A1/en
Publication of JP2024527620A publication Critical patent/JP2024527620A/ja
Publication of JP2024527620A5 publication Critical patent/JP2024527620A5/ja
Pending legal-status Critical Current

Links

JP2024502131A 2021-07-16 2022-07-07 がん幹細胞に対する新規の腫瘍特異的抗原及びそれらの使用 Pending JP2024527620A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163203320P 2021-07-16 2021-07-16
US63/203,320 2021-07-16
PCT/CA2022/051068 WO2023023840A1 (en) 2021-07-16 2022-07-07 Novel tumor-specific antigens for cancer stem cells and uses thereof

Publications (2)

Publication Number Publication Date
JP2024527620A JP2024527620A (ja) 2024-07-25
JP2024527620A5 true JP2024527620A5 (https=) 2025-07-11

Family

ID=85322248

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024502131A Pending JP2024527620A (ja) 2021-07-16 2022-07-07 がん幹細胞に対する新規の腫瘍特異的抗原及びそれらの使用

Country Status (6)

Country Link
US (1) US20240382590A1 (https=)
EP (1) EP4370682A4 (https=)
JP (1) JP2024527620A (https=)
AU (1) AU2022331944A1 (https=)
CA (1) CA3224907A1 (https=)
WO (1) WO2023023840A1 (https=)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2347769A1 (en) * 2010-01-20 2011-07-27 Glycotope GmbH Cancer stem cell markers and uses thereof
CN112639136B (zh) * 2018-08-30 2024-08-02 蒙特利尔大学 用于鉴定肿瘤特异性抗原的基于蛋白质基因组学的方法
BR112021025943A2 (pt) * 2019-06-25 2022-02-08 Univ Montreal Antígenos específicos de tumor inovadores para câncer de ovário e usos dos mesmos

Similar Documents

Publication Publication Date Title
Barzaman et al. Breast cancer immunotherapy: Current and novel approaches
Liu et al. mRNA cancer vaccines: construction and boosting strategies
Yao et al. Recent progress in mRNA cancer vaccines
JP7005346B2 (ja) 養子細胞免疫療法の有効性を増強させるための組成物および方法
ES2835269T5 (en) Claudin-18.2-specific immunoreceptors and t cell epitopes
CN104140974B (zh) 编码gpc‑3嵌合抗原受体蛋白的核酸及表达gpc‑3嵌合抗原受体蛋白的t淋巴细胞
CN104087607B (zh) 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
CN106146666B (zh) 靶向cldn6的免疫效应细胞及其制备方法和应用
JP2021522820A5 (https=)
US20190298715A1 (en) Immune effector cell therapies with enhanced efficacy
JP6621473B2 (ja) 癌の診断および処置のための方法および組成物
WO2015172339A1 (zh) 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
JP2023518396A5 (https=)
JP2024535853A5 (https=)
JP2020533962A5 (https=)
CN110352067A (zh) Hla限制性vgll1肽及其用途
WO2022057941A1 (zh) 表达il-7r结合蛋白的免疫效应细胞
CN114599400A (zh) 用于治疗癌症的医药、组合医药、医药组合物、免疫应答细胞、核酸递送介质和制品
Roesler et al. Beyond sequencing: prioritizing and delivering neoantigens for cancer vaccines
Afzal et al. Current trends in messenger RNA technology for cancer therapeutics
JP2023521219A5 (https=)
JP2024527620A5 (https=)
CN110331134A (zh) 一种表达抗原识别区域的通用型细胞治疗产品及其制备方法和应用
JP2021517454A5 (https=)